Logo image of NMRA

NEUMORA THERAPEUTICS INC (NMRA) Stock Fundamental Analysis

NASDAQ:NMRA - Nasdaq - US6409791000 - Common Stock - Currency: USD

0.84  -0.02 (-2.33%)

Fundamental Rating

2

NMRA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. NMRA has a great financial health rating, but its profitability evaluates not so good. NMRA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NMRA has reported negative net income.
In the past year NMRA has reported a negative cash flow from operations.
In the past 5 years NMRA always reported negative net income.
In the past 5 years NMRA always reported negative operating cash flow.
NMRA Yearly Net Income VS EBIT VS OCF VS FCFNMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

NMRA has a worse Return On Assets (-100.51%) than 75.38% of its industry peers.
The Return On Equity of NMRA (-113.00%) is worse than 60.51% of its industry peers.
Industry RankSector Rank
ROA -100.51%
ROE -113%
ROIC N/A
ROA(3y)-51.72%
ROA(5y)-52.12%
ROE(3y)-56.07%
ROE(5y)-55.97%
ROIC(3y)N/A
ROIC(5y)N/A
NMRA Yearly ROA, ROE, ROICNMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NMRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMRA Yearly Profit, Operating, Gross MarginsNMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

NMRA has more shares outstanding than it did 1 year ago.
NMRA has more shares outstanding than it did 5 years ago.
NMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NMRA Yearly Shares OutstandingNMRA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
NMRA Yearly Total Debt VS Total AssetsNMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

NMRA has an Altman-Z score of -5.05. This is a bad value and indicates that NMRA is not financially healthy and even has some risk of bankruptcy.
NMRA has a Altman-Z score of -5.05. This is in the lower half of the industry: NMRA underperforms 62.05% of its industry peers.
NMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.05
ROIC/WACCN/A
WACCN/A
NMRA Yearly LT Debt VS Equity VS FCFNMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 8.98 indicates that NMRA has no problem at all paying its short term obligations.
NMRA has a better Current ratio (8.98) than 81.54% of its industry peers.
NMRA has a Quick Ratio of 8.98. This indicates that NMRA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.98, NMRA belongs to the top of the industry, outperforming 81.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.98
Quick Ratio 8.98
NMRA Yearly Current Assets VS Current LiabilitesNMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for NMRA have decreased by -4.34% in the last year.
EPS 1Y (TTM)-4.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.54% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0.08%
EPS Next 2Y9.96%
EPS Next 3Y6.5%
EPS Next 5Y13.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NMRA Yearly Revenue VS EstimatesNMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
NMRA Yearly EPS VS EstimatesNMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NMRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NMRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMRA Price Earnings VS Forward Price EarningsNMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMRA Per share dataNMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.96%
EPS Next 3Y6.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NMRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUMORA THERAPEUTICS INC

NASDAQ:NMRA (6/17/2025, 9:31:49 AM)

0.84

-0.02 (-2.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners60.17%
Inst Owner Change-15.65%
Ins Owners5.42%
Ins Owner Change-1.02%
Market Cap135.87M
Analysts74.29
Price Target6.73 (701.19%)
Short Float %12.81%
Short Ratio15.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.35%
Min EPS beat(2)-10.01%
Max EPS beat(2)18.71%
EPS beat(4)2
Avg EPS beat(4)-0.52%
Min EPS beat(4)-13.12%
Max EPS beat(4)18.71%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)16.47%
PT rev (3m)-53.8%
EPS NQ rev (1m)3.43%
EPS NQ rev (3m)3.43%
EPS NY rev (1m)0%
EPS NY rev (3m)7.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)-1.61
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0
BVpS1.41
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -100.51%
ROE -113%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.72%
ROA(5y)-52.12%
ROE(3y)-56.07%
ROE(5y)-55.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.98
Quick Ratio 8.98
Altman-Z -5.05
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1039.1%
Cap/Depr(5y)890.19%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.53%
EPS Next Y0.08%
EPS Next 2Y9.96%
EPS Next 3Y6.5%
EPS Next 5Y13.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-31.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.9%
EBIT Next 3Y13.29%
EBIT Next 5Y11.89%
FCF growth 1Y-71.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.29%
OCF growth 3YN/A
OCF growth 5YN/A